Jazz Pharma downgraded by Cantor Fitzgerald
$JAZZ
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald downgraded Jazz Pharma from Overweight to Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/22/2026 | $229.00 | Mkt Perform | Bernstein |
| 5/19/2026 | $307.00 | Neutral → Buy | UBS |
| 4/10/2026 | $227.00 | Outperform | Raymond James |
| 2/27/2026 | $224.00 | Overweight | Barclays |
| 11/24/2025 | $188.00 | Buy → Neutral | UBS |
| 7/15/2025 | $152.00 | Buy | Deutsche Bank |
| 3/7/2025 | $145.00 → $179.00 | Neutral → Buy | UBS |
| 2/26/2025 | Overweight → Neutral | Cantor Fitzgerald |
4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
144 - Jazz Pharmaceuticals plc (0001232524) (Subject)
PRE 14A - Jazz Pharmaceuticals plc (0001232524) (Filer)
8-K - Jazz Pharmaceuticals plc (0001232524) (Filer)
Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomniaFor U.S. media and investors onlyDUBLIN, June 4, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026, in Baltimore. The robust breadth of data reflects Jazz's continued focus on advancing treatment for rare and difficult-to-treat sleep disorders with new clinical research and real-world evidence evalua
Expanded safety, subgroup, progression-free survival sensitivity and subsequent therapy analyses further characterize the consistency and durability of outcomes observed with zanidatamab-containing combinations in the first-line settingAdditional subgroup analyses to be presented at the 2026 ASCO Annual Meeting show improved clinical outcomes with zanidatamab-containing combinations regardless of PD-L1 expression, including in PD-L1-negative patientsFor U.S. media and investors only DUBLIN, May 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the New England Journal of Medicine has published the Phase 3 HERIZON-GEA-01 trial results, further characterizing
DUBLIN, May 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that company management will participate in fireside chats at the following investor conferences:2026 RBC Global Healthcare Conference on Tuesday, May 19, 2026 at 8:00 a.m. ETTD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May 27, 2026 at 2:00 p.m. ET2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 10:30 a.m. ETAudio webcasts of the fireside chats will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be archived on the
Bernstein initiated coverage of Jazz Pharma with a rating of Mkt Perform and set a new price target of $229.00
UBS upgraded Jazz Pharma from Neutral to Buy and set a new price target of $307.00
Raymond James resumed coverage of Jazz Pharma with a rating of Outperform and set a new price target of $227.00
4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
For Immediate Release: August 12, 2021 The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia (IH) in adults. IH is an uncommon chronic sleep disorder that causes people to be excessively sleepy during the day even after a good night's sleep. Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution is already approved for the treatment of catapl
Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions DUBLIN, Jan. 8, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026. Mr. Riga joined Jazz in April 2025 through the acquisition of Chimerix Inc., where he served as chief operating and commercial officer. In that role, he directed corporate strategy including the successful sale of Chimerix to Jazz. In addition to leading the transaction process and alliance management at Chimerix, he helped navigate a complex regulatory env
Dr. Love, a biopharmaceutical industry veteran, brings extensive executive leadership and board experience with proven success in creating shareholder value DUBLIN, Oct. 28, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that Ted W. Love, M.D., has been appointed to the Company's Board of Directors, effective December 1, 2025. Dr. Love brings more than 30 years of expertise in drug development and global commercialization to the Company's Board. "We are thrilled to welcome Ted to the Board," said Renee Gala, president and CEO, Jazz Pharmaceuticals. "His proven success in the biopharmaceutical industry and track record driving scientific innovation, commercial su
– Selection Follows Robust Succession Process Led by the Board – – Bruce Cozadd to Retire as CEO and Remain Chairperson of the Board of Directors – DUBLIN, July 10, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Jazz Board of Directors has unanimously selected Renee Gala, Jazz's President and Chief Operating Officer, as the President and Chief Executive Officer, effective August 11, 2025, when she will also join the Board. She will succeed co-founder, Chairperson and CEO Bruce Cozadd, who informed the Board in December 2024 of his intent to retire as CEO upon the identification of the Company's next leader. This appointment reflects a key milestone in t
– Strong commercial execution across franchises with total revenues of $1.1 billion (+19% YoY) –– Zanidatamab HER2+ 1L GEA sBLA granted Priority Review; PDUFA date of August 25, 2026 –– Xywav® revenues grew 18% YoY with 425 net patient adds –– Epidiolex® revenues grew 15% YoY–– Company reaffirms 2026 revenue and expense guidance –DUBLIN, May 5, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the first quarter of 2026 (1Q26)."Our first-quarter results reflect disciplined execution across the business, delivering 19% year-over-year growth alongside key pipeline advancements and positioning the company for an outstanding 2026," said Renee Gala,
DUBLIN, April 21, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced it will report its 2026 first quarter financial results on Tuesday, May 5, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET to discuss the results and provide a business and financial update.Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.A replay of the webcast will be available via the Investors section of
– Record total revenues of $4.3 billion in 2025 (+5% YoY) and $1.2 billion (+10% YoY) in 4Q25 –– Expect to complete sBLA submission in 1Q26 under RTOR for zanidatamab in HER2+ 1L GEA –– Xywav® achieved $1.7 billion in revenue and 12% YoY growth in 2025 –– Epidiolex® achieved $1.1 billion in revenue and 9% YoY growth in 2025 –– Strong Modeyso™ launch with $37 million in revenue in first full quarter on market –– Expect 2026 total revenues of $4.25 to $4.50 billion –DUBLIN, Feb. 24, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the full year and fourth quarter of 2025 and provided financial guidance for 2026."2025 was an exceptional year for
SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)
SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)
SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)